Skip to main content

Advertisement

Log in

The Influence of Oral Cannabidiol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Untreated Hypertension: A Double-Blind, Placebo-Controlled, Cross-Over Pilot Study

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Studies reveal that cannabidiol may acutely reduce blood pressure and arterial stiffness in normotensive humans; however, it remains unknown if this holds true in patients with untreated hypertension. We aimed to extend these findings to examine the influence of the administration of cannabidiol on 24-h ambulatory blood pressure and arterial stiffness in hypertensive individuals.

Methods

Sixteen volunteers (eight females) with untreated hypertension (elevated blood pressure, stage 1, stage 2) were given oral cannabidiol (150 mg every 8 h) or placebo for 24 h in a randomised, placebo-controlled, double-blind, cross-over study. Measures of 24-h ambulatory blood pressure and electrocardiogram (ECG) monitoring and estimates of arterial stiffness and heart rate variability were obtained. Physical activity and sleep were also recorded.

Results

Although physical activity, sleep patterns and heart rate variability were comparable between groups, arterial stiffness (~ 0.7 m/s), systolic blood pressure (~ 5 mmHg), and mean arterial pressure (~ 3 mmHg) were all significantly (P < 0.05) lower over 24 h on cannabidiol when compared to the placebo. These reductions were generally larger during sleep. Oral cannabidiol was safe and well tolerated with no development of new sustained arrhythmias.

Conclusions

Our findings indicate that acute dosing of cannabidiol over 24 h can lower blood pressure and arterial stiffness in individuals with untreated hypertension. The clinical implications and safety of longer-term cannabidiol usage in treated and untreated hypertension remains to be established.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Kovalchuk O, Kovalchuk I. Cannabinoids as anticancer therapeutic agents. Cell Cycle. 2020. https://doi.org/10.1080/15384101.2020.1742952.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Klimkiewicz A, Jasinska A. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Acad Sci Eng Med 2017.

  3. Sultan SR, Millar SA, England TJ, O’Sullivan SE. A systematic review and meta-analysis of the haemodynamic effects of cannabidiol. Front Pharmacol. 2017;8:1–13.

    Article  Google Scholar 

  4. Alfulaij N, Meiners F, Michalek J, Small-Howard AL, Turner HC, Stokes AJ. Cannabinoids, the heart of the matter. J Am Heart Assoc. 2018;7:1–10.

    Article  Google Scholar 

  5. Atalay S, Jarocka-karpowicz I, Skrzydlewskas E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants. 2019;9:1–20.

    Article  Google Scholar 

  6. Richter JS, Quenardelle V, Rouyer O, Raul JS, Beaujeux R, Gény B, et al. A systematic review of the complex effects of cannabinoids on cerebral and peripheral circulation in animal models. Front Physiol. 2018;9:00662.

    Article  Google Scholar 

  7. Resstel LBM, Joca SRL, Moreira FA, Corrêa FMA, Guimarães FS. Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behav Brain Res. 2006;172:294–8.

    Article  PubMed  Google Scholar 

  8. Granjeiro ÉM, Gomes FV, Guimarães FS, Corrêa FMA, Resstel LBM. Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress. Pharmacol Biochem Behav. 2011;99:743–8. https://doi.org/10.1016/j.pbb.2011.06.027.

    Article  CAS  PubMed  Google Scholar 

  9. Gomes FV, Reis DG, Alves FHF, Corrêa FMA, Guimarães FS, Resstel LBM. Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT 1A receptors. J Psychopharmacol. 2012;26:104–13.

    Article  CAS  PubMed  Google Scholar 

  10. Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol. 1993;7:82–8.

    Article  CAS  PubMed  Google Scholar 

  11. Arout CA, Haney M, Herrmann ES, Bedi G, Cooper ZD. A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans. Br J Clin Pharmacol. 2022;88:347–55.

    Article  CAS  PubMed  Google Scholar 

  12. Jadoon KA, Tan GD, O’sullivan SE. A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight. 2017;2:1–11.

    Article  Google Scholar 

  13. Sultan SR, O’Sullivan SE, England TJ. The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: a randomised controlled trial. Br J Clin Pharmacol. 2019;86:1125–38.

    Article  Google Scholar 

  14. Safar ME, Asmar R, Benetos A, Blacher J, Boutouyrie P, Lacolley P, et al. Interaction between hypertension and arterial stiffness an expert reappraisal. Hypertension. 2018;72:796–805.

    Article  CAS  PubMed  Google Scholar 

  15. Remiszewski P, Jarocka-Karpowicz I, Biernacki M, Jastrząb A, Schlicker E, Toczek M, et al. Chronic cannabidiol administration fails to diminish blood pressure in rats with primary and secondary hypertension despite its effects on cardiac and plasma endocannabinoid system, oxidative stress and lipid metabolism. Int J Mol Sci. 2020;21:1–24.

    Article  Google Scholar 

  16. Pacher P, Bátkai S, Kunos G. Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology. 2005;48:1130–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Yano Y, Reis JP, Colangelo LA, Shimbo D, Viera AJ, Allen NB, et al. Association of Blood Pressure Classification in Young Adults Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline with Cardiovascular Events Later in Life. JAMA J Am Med Assoc. 2018;320:1774–82.

    Article  Google Scholar 

  18. Kumric M, Bozic J, Dujic G, Vrdoljak J, Dujic Z. Chronic effects of effective oral cannabidiol delivery on 24-h ambulatory blood pressure and vascular outcomes in treated and untreated hypertension (HYPER-H21–4): study protocol for a randomized placebo-controlled, and crossover study. J Pers Med. 2022;12:1037.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension. 2019.

  20. Perucca E, Bialer M. Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications. CNS Drugs. 2020;34:795–800. https://doi.org/10.1007/s40263-020-00741-5.

    Article  CAS  PubMed  Google Scholar 

  21. Birnbaum AK, Karanam A, Marino SE, Barkley CM, Remmel RP, Roslawski M, et al. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia. 2019;60:1586–92.

    Article  CAS  PubMed  Google Scholar 

  22. Tedesco S, Sica M, Ancillao A, Timmons S, Barton J, O’Flynn B. Validity evaluation of the fitbit charge2 and the garmin vivosmart HR+ in free-living environments in an older adult cohort. JMIR mHealth uHealth. 2019;7:1–15.

    Article  Google Scholar 

  23. Kiviniemi AM, Perkiömäki N, Auvinen J, Niemelä M, Tammelin T, Puukka K, et al. Fitness, fatness, physical activity, and autonomic function in midlife. Med Sci Sports Exerc. 2017;49:2459–68.

    Article  PubMed  Google Scholar 

  24. Tulppo M, Huikuri HV. Origin and significance of heart rate variability. J Am Coll Cardiol. 2004;43:2278–80. https://doi.org/10.1016/j.jacc.2004.03.034.

    Article  PubMed  Google Scholar 

  25. Weber T, Auer J, O’Rourke MF, Kvas E, Lassnig E, Berent R, et al. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation. 2004;109:184–9.

    Article  PubMed  Google Scholar 

  26. Wassertheurer S, Kropf J, Weber T, Van Der Giet M, Baulmann J, Ammer M, et al. A new oscillometric method for pulse wave analysis: comparison with a common tonometric method. J Hum Hypertens. 2010;24:498–504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Lenth R V. emmeans: estimated marginal means, aka least-squares means. 2022. p. R package version 1.7.4-1.

  28. Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models. J Stat Softw. 2017;82:1–26.

    Article  Google Scholar 

  29. WHO. Cannabidiol (CBD): World Health Organization Expert Committee on drug dependence thirty‐ninth meeting [Internet]. World Heal. Organ. Tech. Rep. Ser. 2017. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32310508.

  30. Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46:86–95.

    Article  CAS  PubMed  Google Scholar 

  31. Jones RT. Cardiovascular system effects of marijuana. J Clin Pharmacol. 2002;42:58–63.

    Article  Google Scholar 

  32. Mathew RJ, Wilson WH, Humphreys D, Lowe JV, Wiethe KE. Middle cerebral artery velocity during upright posture after marijuana smoking. Acta Psychiatr Scand. 1992;86:173–8.

    Article  CAS  PubMed  Google Scholar 

  33. Stanley CP, Hind WH, Tufarelli C, O’Sullivan SE. Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation. Cardiovasc Res. 2015;107:568–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Niederhoffer N, Schmid K, Szabo B. The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn Schmiedebergs Arch Pharmacol. 2003;367:434–43.

    Article  CAS  PubMed  Google Scholar 

  35. Dean C. Cannabinoid and GABA modulation of sympathetic nerve activity and blood pressure in the dorsal periaqueductal gray of the rat. Am J Physiol Regul Integr Comp Physiol. 2011;301:1765–72.

    Article  Google Scholar 

  36. Kumric M, Dujic G, Vrdoljak J, Svagusa K, Kurir TT, Supe-Domic D, et al. CBD supplementation reduces arterial blood pressure via modulation of the sympatho-chromaffin system: a substudy from the HYPER-H21–4 trial. Biomed Pharmacother. 2023;160:114387. https://doi.org/10.1016/j.biopha.2023.114387.

    Article  CAS  PubMed  Google Scholar 

  37. Abuhasira R, Haviv YS, Leiba M, Leiba A, Ryvo L, Novack V. Cannabis is associated with blood pressure reduction in older adults—a 24-hours ambulatory blood pressure monitoring study. Eur J Intern Med. 2021;86:79–85. https://doi.org/10.1016/j.ejim.2021.01.005.

    Article  PubMed  Google Scholar 

  38. Wheal AJ, Cipriano M, Fowler CJ, Randall MD, O’Sullivan SE. Cannabidiol improves vasorelaxation in Zucker diabetic fatty rats through cyclooxygenase activation. J Pharmacol Exp Ther. 2014;351:457–66.

    Article  PubMed  Google Scholar 

  39. Baranowska-Kuczko M, Kozłowska H, Kloza M, Sadowska O, Kozłowski M, Kusaczuk M, et al. Vasodilatory effects of cannabidiol in human pulmonary and rat small mesenteric arteries: modification by hypertension and the potential pharmacological opportunities. J Hypertens. 2020;38:896–911.

    Article  CAS  PubMed  Google Scholar 

  40. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HHO, Das SK, et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest. 1997;100:1538–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Joyner MJ, Dietz NM. Nitric oxide and vasodilation in human limbs. J Appl Physiol. 1997;83:1785–96.

    Article  CAS  PubMed  Google Scholar 

  42. O’Sullivan SE, Kendall DA, Randall MD. Further characterization of the time-dependent vascular effects of Δ9-tetrahydrocannabinol. J Pharmacol Exp Ther. 2006;317:428–38.

    Article  PubMed  Google Scholar 

  43. Grassi G, Bombelli M, Seravalle G, Dell’Oro R, Quarti-Trevano F. Diurnal blood pressure variation and sympathetic activity. Hypertens Res. 2010;33:381–5.

    Article  PubMed  Google Scholar 

  44. Kumric M, Vrdoljak J, Dujic G, Supe-Domic D, Ticinovic Kurir T, Dujic Z, et al. Serum catestatin levels correlate with ambulatory blood pressure and indices of arterial stiffness in patients with primary hypertension. Biomolecules. 2022;12:1204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Meng L, Ye XJ, Ding WH, Yang Y, Di BB, Liu L, et al. Plasma catecholamine release-inhibitory peptide catestatin in patients with essential hypertension. J Cardiovasc Med. 2011;12:643–7.

    Article  Google Scholar 

  46. Kiranmayi M, Chirasani VR, Allu PKR, Subramanian L, Martelli EE, Sahu BS, et al. Catestatin Gly364Ser variant alters systemic blood pressure and the risk for hypertension in human populations via endothelial nitric oxide pathway. Hypertension. 2016;68:334–47.

    Article  CAS  PubMed  Google Scholar 

  47. Zalewska E, Kmieć P, Sworczak K. Role of catestatin in the cardiovascular system and metabolic disorders. Front Cardiovasc Med. 2022;9:1–14.

    Article  Google Scholar 

  48. Valensi P. Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications. Cardiovasc Diabetol. 2021;20(1):12. https://doi.org/10.1186/s12933-021-01356-w.

    Article  Google Scholar 

  49. Pędzińska-Betiuk A, Weresa J, Schlicker E, Harasim-Symbor E, Toczek M, Kasacka I, et al. Chronic cannabidiol treatment reduces the carbachol-induced coronary constriction and left ventricular cardiomyocyte width of the isolated hypertensive rat heart. Toxicol Appl Pharmacol. 2021;411:115368.

    Article  PubMed  Google Scholar 

  50. Remiszewski P, Malinowska B. Why multitarget vasodilatory (endo)cannabinoids are not effective as antihypertensive compounds after chronic administration: comparison of their effects on systemic and pulmonary hypertension. Pharmaceuticals. 2022;15:1119.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015;172:737–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG. Evidence that the plant cannabinoid cannabigerol is a highly potent α 2-adrenoceptor agonist and moderately potent 5HT 1A receptor antagonist. Br J Pharmacol. 2010;159:129–41.

    Article  CAS  PubMed  Google Scholar 

  53. Cathel AM, Reyes BAS, Wang Q, Palma J, Mackie K, Van Bockstaele EJ, et al. Cannabinoid modulation of alpha2 adrenergic receptor function in rodent medial prefrontal cortex. Eur J Neurosci. 2014;40:3202–14.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Giovannitti JA, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: A review of current clinical applications. Anesth Prog. 2015;62:31–8.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Hermann M, Flammer A, Lüscher TF. Nitric oxide in hypertension. J Clin Hypertens. 2006;8:17–29.

    Article  CAS  Google Scholar 

  56. McCollum LT, Howlett AC, Mukhopadhyay S. Anandamide-mediated CB1/CB2 cannabinoid receptor-independent nitric oxide production in rabbit aortic endothelial cells. J Pharmacol Exp Ther. 2007;321:930–7.

    Article  CAS  PubMed  Google Scholar 

  57. Fok H, Jiang B, Clapp B, Chowienczyk P. Regulation of vascular tone and pulse wave velocity in human muscular conduit arteries: selective effects of nitric oxide donors to dilate muscular arteries relative to resistance vessels. Hypertension. 2012;60:1220–5.

    Article  CAS  PubMed  Google Scholar 

  58. Wilkinson IB, Mceniery CM. Arterial stiffness, endothelial function and novel pharmacological approaches. Clin Exp Pharmacol Physiol. 2004;31:795–9.

    Article  CAS  PubMed  Google Scholar 

  59. Bruno RM, Ghiadoni L, Seravalle G, Dell’Oro R, Taddei S, Grassi G. Sympathetic regulation of vascular function in health and disease. Front Physiol. 2012;3(JUL):1–15.

    Google Scholar 

  60. Sidney S. Cardiovascular consequences of marijuana use. J Clin Pharmacol. 2002;42:64–70.

    Article  Google Scholar 

  61. Laurikainen H, Tuominen L, Tikka M, Merisaari H, Armio RL, Sormunen E, et al. Sex difference in brain CB1 receptor availability in man. Neuroimage. 2019;184:834–42.

    Article  CAS  PubMed  Google Scholar 

  62. Verdecchia P, Gentile G, Angeli F, Mazzotta G, Mancia G, Reboldi G. Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens. 2010;28:1356–65.

    Article  CAS  PubMed  Google Scholar 

  63. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness. A systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318–27. https://doi.org/10.1016/j.jacc.2009.10.061.

    Article  PubMed  Google Scholar 

  64. SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. N Engl J Med. 2015;373:2103–16.

    Article  Google Scholar 

  65. Kario K. Morning surge in blood pressure and cardiovascular risk: Evidence and perspectives. Hypertension. 2010;56:765–73.

    Article  CAS  PubMed  Google Scholar 

  66. Diederichsen SZ, Haugan KJ, Kronborg C, Graff C, Højberg S, Køber L, et al. Comprehensive evaluation of rhythm monitoring strategies in screening for atrial fibrillation: insights from patients at risk monitored long term with an implantable loop recorder. Circulation. 2020;141:1510–22.

    Article  PubMed  Google Scholar 

  67. Patrician A, Versic-Bratincevic M, Mijacika T, Banic I, Marendic M, Sutlović D, et al. Examination of a new delivery approach for oral cannabidiol in healthy subjects: a randomized, double-blinded placebo-controlled pharmacokinetics study. Adv Ther. 2019;36:3196–210.

    Article  CAS  PubMed  Google Scholar 

  68. Zendulka O, Dovrtělová G, Nosková K, Turjap M, Šulcová A, Hanuš L, et al. Cannabinoids and cytochrome P450 interactions. Curr Drug Metab. 2016;17:206–26.

    Article  CAS  PubMed  Google Scholar 

  69. Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58:1586–92.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Funding

Sponsorship for the present study were funded by Lexaria Bioscience Corp. (Kelowna, BC, Canada). The funds provided by the sponsor to the authors were used to fund the Rapid Service Journal associated with Advances in Therapy.

Author Contributions

Study design: Zeljko Dujic; Data collection: Tanja Dragun, Ante Obad, Mikko Tulppo; Data Analyses: Mikko Tulppo, Courtney Brown. Original draft of manuscript was prepared by Tanja Dragun and Courtney Brown and all authors were involved in reviewing and editing the final version of the manuscript.

Disclosures

All authors, including Tanja Dragun, Courtney V. Brown, Mikko P. Tulppo, Ante Obad and Željko Dujić, declare that the study was sponsored by Lexaria Bioscience Corp., the company which manufactures the DehydraTECHTM2.0 used in the present study. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

Compliance with Ethics Guidelines

The protocol, and all methods included, in the present study were reviewed and approved by the ethics review board at the University of Split, School of Medicine (certificate number: 2181-198-03-04-21-0001) and conformed to the latest revision of the Declarataion of Helsinki, except for registration in a data base. All participants provided written, informed consent prior to enrolling in the study.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Željko Dujić.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 43 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dragun, T., Brown, C.V., Tulppo, M.P. et al. The Influence of Oral Cannabidiol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Untreated Hypertension: A Double-Blind, Placebo-Controlled, Cross-Over Pilot Study. Adv Ther 40, 3495–3511 (2023). https://doi.org/10.1007/s12325-023-02560-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-023-02560-8

Keywords

Navigation